Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients
PLOS One · 2025
DOI: 10.1371/journal.pone.0329263 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Wahby M Babaresh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Peshawar, Pakistan. Hauptthemen laut MEDLINE: Amlodipine, Hypertension, Calcium Channels, L-Type, Antihypertensive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Research Programme for Universities (NRPU), HEC.
Abstract (Originalsprache)
Hypertension affects over 1.28 billion individuals worldwide, yet response variability to calcium channel blockers (CCBs) like amlodipine remains a challenge. While pharmacogenomic studies have implicated genetic polymorphisms in treatment outcomes, the combined effects of multiple variants remain unclear. This study investigates the influence of CACNA1D (rs3774426), CACNA1C (rs2239050, rs7311382), and TRIB3 (rs2295490) variants, individually and in combination, on the antihypertensive response to amlodipine. A total of 133 hypertensive patients from Khyber Pakhtunkhwa, Pakistan, receiving amlodipine monotherapy were genotyped using ARMS-PCR and Sanger sequencing. Blood pressure response was defined as post-treatment systolic blood pressure (SBP) ≤140 mmHg and diastolic blood pressure (DBP) ≤90 mmHg. Statistical analyses were adjusted for age, gender, BMI, dose, family history of HTN and dietary habits. The CACNA1D rs3774426 TT genotype was significantly associated with non-response in 35 patients, showing higher SBP than the CC genotype (n = 69). Conversely, the CACNA1C rs2239050 GG genotype (n = 67) was linked to improved SBP and DBP control compared to the CC genotype (n = 25). Combined genotype models ( CACNA1D – CACNA1C and CACNA1D – CACNA1C – TRIB3 ) showed strong unadjusted associations but lost significance after adjustment. These findings highlight the role of CACNA1D rs3774426 in predicting amlodipine non-response and demonstrate the potential of genetic screening for optimizing antihypertensive therapy. Integrating pharmacogenomics into clinical practice could enhance personalized treatment strategies, improving outcomes in hypertensive patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Peshawar, Pakistan.
- Faculty of Pharmacy, University of Aden, Yemen.
- Department of Pharmacy, University of Swabi, Swabi, Pakistan.
- The Lady Reading Hospital Medical Teaching Institution, Peshawar, Pakistan.
- Cardiology Ward, Hayat Medical Complex Hospital, Peshawar, Pakistan.
- Institute of Pharmaceutical Sciences, Khyber Medical University, Peshawar, Pakistan.
ORCID-Profile: Wahby M Babaresh, Zakiullah, Sohaib Ahmad Sohail, Haseenullah Shah
Förderung
- the National Research Programme for Universities (NRPU), HEC
Zitieren
APA
Babaresh, W. M., Zakiullah, Sohail, S. A., Baig, A., Faisal, M., Begum, A., Shah, H., Ul Hassan, Z., Ijaz, K., Shah, S. M. M., & Ullah, A. (2025). Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients. PLOS One. https://doi.org/10.1371/journal.pone.0329263
Vancouver
Babaresh WM, Zakiullah, Sohail SA, Baig A, Faisal M, Begum A, et al. Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients. PLOS One. 2025. doi:10.1371/journal.pone.0329263
BibTeX
@article{Babaresh2025,
author = {Babaresh, Wahby M and Zakiullah and Sohail, Sohaib Ahmad and Baig, Alija and Faisal, Malik and Begum, Aiman and Shah, Haseenullah and Ul Hassan, Zia and Ijaz, Kiran and Shah, Syed Muhammad Mukarram and Ullah, Aftab},
title = {Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0329263}
}
EUVIMED